Phaseline

Companies › Ashibio

Ashibio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology, Other; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Andecaliximab
Matrix metalloproteinase 9 inhibitor
MMP9Phase 2Fibrodysplasia Ossificans Progressiva; Heterotopic Ossification (HO)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07024407AndecaliximabPhase 1Heterotopic Ossification (HO)OtherDec 2028
NCT06508021AndecaliximabPhase 2Fibrodysplasia Ossificans ProgressivaImmunologyFeb 2029

Targets

MMP9 (1)

Companies with the same targets

–

Companies built like this

RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) AnaptysBio Q32 Bio Clarent Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.